Survey Reveals Life Sciences Quality Assurance Discipline Set to See Extensive Recruitment Activity
The Quality Assurance (QA) discipline within the life sciences sector is set to see extensive employment changes as salary dissatisfaction drives career moves, according to new research by life sciences recruiter, Clinical Professionals.
In its comprehensive salary survey of the life sciences sector, Clinical Professionals found that 75% of candidates in the QA field felt their pay did not reflect their level of experience. While this is a 5% on last year’s report, it is one of the highest percentages recorded across the life sciences sector. The report goes on to outline that, as a result of this dissatisfaction, more than half of those questioned (59%) plan to move jobs in the next year, with a further 18% stating they would take a new role in the next 12 months if the package was right.
In an attempt to counter this negativity, employers remain focussed on training and development of staff in order to support internal promotions. There was a clear growth in the range of QA career options, with the type and number of job titles noted in this report outstripping those from the 2012. Training and development budgets appear to be on the up with this reported as the third most common benefit. Almost 70% of respondents cited that this option is offered in their current position — a 30% increase on last year’s figures.
Clinical Professionals’ Group Managing Director, Yvette Cleland commented: “With the economic turmoil now behind us, it’s perhaps unsurprising that professionals in the QA arena are beginning to look at new career options. While the increasing use of benefits as a motivator of staff goes some way in keeping staff happy, this consistently high level of salary dissatisfaction means that employers may need to take swift action on basic pay if they are to avoid a resurgence of the long-dormant war for talent.”
The full report is available to view online: www.pharmaceuticalsalarysurvey.com
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance